{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T21:24:47Z","timestamp":1649193887817},"reference-count":9,"publisher":"Pharmaceutical Society of Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["YAKUGAKU ZASSHI"],"published-print":{"date-parts":[[2014,2,1]]},"DOI":"10.1248\/yakushi.13-00211","type":"journal-article","created":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T23:16:13Z","timestamp":1391210173000},"page":"293-298","source":"Crossref","is-referenced-by-count":2,"title":["Examination of the Cause of Changing Solution Color by Mixing Aminophylline and Dopamine, the Compatibility of Which Was Indicated by the Supplier"],"prefix":"10.1248","volume":"134","author":[{"given":"Kazuhiko","family":"Igarashi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Kanazawa Municipal Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Kawahara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kanazawa Municipal Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Shoji T., <i>Iyaku Journal<\/i>, <b>35<\/b>, 2421-2430 (1999)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kaneko T., Ito T., Shoji T., Nakagawa Y., <i>Jpn. J. Hosp. Pharm.<\/i>, <b>17<\/b>, 108-117 (1991).","DOI":"10.5649\/jjphcs1975.17.108"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Asahara K., Yamada H., Yoshida S., Hirose S., <i>Jpn. J. Hosp. Pharm.<\/i>, <b>10<\/b>, 437-445 (1984).","DOI":"10.5649\/jjphcs1975.10.437"},{"key":"4","unstructured":"4) Neophyllin<sup>&reg;<\/sup> Injection 250 mg, Drug interview form, Eisai Co., Ltd., Tokyo, Deccember 2012."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Moriyama M., Furuya K., Suzuki Y., Kondou A., Isoya M., <i>Yakkyoku<\/i>, <b>28<\/b>(4), 61-65 (1977).","DOI":"10.1088\/0031-9112\/28\/2\/021"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Gardella. L. A., Zaroslinski J. F., Possley L. H., <i>Am. J. Hosp. Pharm.<\/i>, <b>32<\/b>, 575-578 (1975).","DOI":"10.1093\/ajhp\/32.6.575"},{"key":"7","unstructured":"7) CATABON<sup>&reg;<\/sup> Hi Inj. 600 mg, Drug interview form, Teva Pharma Japan Inc., Nagoya, April 2012."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Matsumoto S., Yumoto T., Tanabe T., Koyama S., Mizukami Y., <i>Jpn. J. Pharm. Health Care Sci.<\/i>, <b>31<\/b>, 367-374 (2005).","DOI":"10.5649\/jjphcs.31.367"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Swan G. A., <i>Ann. N.Y. Acad. Sci.<\/i>, <b>100<\/b>, 1005-1019 (1963).","DOI":"10.1111\/j.1749-6632.1963.tb42905.x"}],"container-title":["YAKUGAKU ZASSHI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yakushi\/134\/2\/134_13-00211\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T06:10:03Z","timestamp":1565158203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yakushi\/134\/2\/134_13-00211\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,1]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1248\/yakushi.13-00211","relation":{},"ISSN":["0031-6903","1347-5231"],"issn-type":[{"value":"0031-6903","type":"print"},{"value":"1347-5231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,1]]}}}